enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update

– Quarter marked by corporate rebranding and strategic prioritization of development programs – Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for severe deep venous Chronic Venous Insufficiency (CVI) – Bolstered cash position with recently completed $20 million registered direct offering with leading life sciences investment firm

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

5 COMMENTS

Cancel reply

Please enter your comment!
Please enter your name here